INTEGRA Biosciences unveils the SWITCH hybrid pipette combining manual control with fast electronic aliquoting Post author:admin Post published:September 19, 2025 Post category:uncategorized INTEGRA Biosciences is excited to announce the launch of its new SWITCH hybrid pipette, available from September 2025. You Might Also Like Therapeutic potential of CD20 x CD3 bispecific antibodies April 5, 2024 Pheno Therapeutics granted clinical trial authorization for lead multiple sclerosis therapeutic candidate PTD802 January 15, 2025 Howard Hughes Medical Institute announces $500 million to support AI-driven projects in life sciences August 12, 2024
Pheno Therapeutics granted clinical trial authorization for lead multiple sclerosis therapeutic candidate PTD802 January 15, 2025
Howard Hughes Medical Institute announces $500 million to support AI-driven projects in life sciences August 12, 2024